Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase

Journal of Medicinal Chemistry

Volumn 54, Issue 6, 2011, Pages 1613-1625

  Stefanachi, Angela ^a   Favia, Angelo D ^b   Nicolotti, Orazio ^a   Leonetti, Francesco ^a   Pisani, Leonardo ^a   Catto, Marco ^a   Zimmer, Christina ^c   Hartmann, Rolf W ^c   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1H IMIDAZOL 1 YLMETHYL) 7 (3 METHOXYPHENOXY) 2H CHROMEN 2 ONE; 4 (1H IMIDAZOL 1 YLMETHYL) 7 (4 METHOXYPHENOXY) 2H CHROMEN 2 ONE; 4 (1H IMIDAZOL 1 YLMETHYL) 7 [(3 METHYLBENZYL)OXY] 2H CHROMEN 2 ONE; 4 (1H IMIDAZOL 1 YLMETHYL) 7 [(3 NITROBENZYL)OXYL] 2H CHROMEN 2 ONE; 4 (1H IMIDAZOL 1 YLMETHYL) 7 [(4 METHOXYBENZYL)OXY] 2H CHROMEN 2 ONE; 4 (1H IMIDAZOL 1 YLMETHYL) 7 [(4 TRIFLUOROMETHOXYBENZYL)OXY] 2H CHROMEN 2 ONE; 4 (1H IMIDAZOL 1 YLMETHYL) 7 [[3 (TRIFLUOROMETHOXY)BENZYL]OXY] 2H CHROMEN 2 ONE; 4 (1H IMIDAZOL 1 YLMETHYL) 7 [[3 (TRIFLUOROMETHYL)BENZYL]OXY] 2H CHROMEN 2 ONE; 4 [[4 (1H IMIDAZOL 1 YLMETHYL) 2 OXO 2H CHROMEN 7 YL]OXY]BENZONITRILE; 7 (3 CHLOROPHENOXY) 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 (3 FLUOROPHENOXY) 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 (3,4 DIFLUOROPHENOXY) 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 (3,4 DIFLUOROPHENOXY) 4 IMIDAZOLYLMETHYL COUMARIN; 7 (3,5 DIFLUOROPHENOXY) 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 (4 ACETYLPHENOXY) 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 (4 CHLOROPHENOXY) 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 [(3 CHLOROBENZYL)OXY] 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 [(3 FLUOROBENZYL)OXY] 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 [(3,4 DIFLUOROBENZYL)OXY] 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 [(3,5 DIFLUOROBENZYL)OXY] 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 [(4 CHLOROBENZYL)OXY] 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 [(4 FLUOROBENZYL)OXY] 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 [4 (DIMETHYLAMINO)PHENOXY] 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; 7 HYDROXY 4 (1H IMIDAZOL 1 YLMETHYL) 2H CHROMEN 2 ONE; AROMATASE INHIBITOR; COUMARIN DERIVATIVE; IMIDAZOLE DERIVATIVE; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN;

AROMATASE INHIBITORS; CELL LINE; COUMARINS; DRUG DESIGN; ESCHERICHIA COLI; FEMALE; HUMANS; IMIDAZOLES; LIGANDS; MICROSOMES; MODELS, MOLECULAR; PLACENTA; PREGNANCY; PROTEIN BINDING; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952810375     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101120u     Document Type: Article

References (71)

1. Amir, E.; Freedman, O. C.; Seruga, B.; Evans, D. G. Assessing women at high risk of breast cancer: A review of risk assessment models J. Natl. Cancer Inst. 2010, 102, 680-691
2. Grodin, J. M.; Siiteri, P. K.; MacDonald, P. C. Source of estrogen production in postmenopausal women J. Clin. Endocrinol. Metab. 1973, 36, 207-214
3. O'Neill, J. S.; Elton, R. A.; Miller, W. R. Aromatase activity in adipose tissue from breast quadrants: A link with tumour site Br. Med. J. (Clin. Res. Ed.) 1988, 296, 741-743 (Pubitemid 18066503)
4. Thorsen, T.; Tangen, M.; Stoa, K. F. Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol Eur. J. Cancer Clin. Oncol. 1982, 18, 333-337 (Pubitemid 12092934)
5. Blankenstein, M. A.; Szymczak, J.; Daroszewski, J.; Milewicz, A.; Thijssen, J. H. Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons Gynecol. Endocrinol. 1992, 6, 13-17
6. Banting, L.; Nicholls, P. J.; Shaw, M. A.; Smith, H. J. Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer Prog. Med. Chem. 1989, 26, 253-298
7. Lonard, D. M.; Smith, C. L. Molecular perspectives on selective estrogen receptor modulators (SERMs): Progress in understanding their tissue-specific agonist and antagonist actions Steroids 2002, 67, 15-24 (Pubitemid 33112000)
8. Park, W. C.; Jordan, V. C. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention Trends Mol. Med. 2002, 8, 82-88 (Pubitemid 34094444)
9. Vogel, V. G.; Costantino, J. P.; Wickerham, D. L.; Cronin, W. M.; Cecchini, R. S.; Atkins, J. N.; Bevers, T. B.; Fehrenbacher, L.; Pajon, E. R., Jr.; Wade, J. L., 3rd; Robidoux, A.; Margolese, R. G.; James, J.; Lippman, S. M.; Runowicz, C. D.; Ganz, P. A.; Reis, S. E.; McCaskill-Stevens, W.; Ford, L. G.; Jordan, V. C.; Wolmark, N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial J. Am. Med. Assoc. 2006, 295, 2727-2741
10. Fisher, B.; Costantino, J. P.; Redmond, C. K.; Fisher, E. R.; Wickerham, D. L.; Cronin, W. M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 1994, 86, 527-537 (Pubitemid 24111008)
11. Jordan, V. C. Tamoxifen: Toxicities and drug resistance during the treatment and prevention of breast cancer Annu. Rev. Pharmacol. Toxicol. 1995, 35, 195-211
12. Silverman, S. L. New Selective Estrogen Receptor Modulators (SERMs) in Development Curr. Osteoporosis Rep. 2010, 8, 151-153
13. Baum, M.; Buzdar, A. U.; Cuzick, J.; Forbes, J.; Houghton, J.; Klijn, J. G. M.; Sahmoud, T.; Grp, A. T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial Lancet 2002, 359, 2131-2139 (Pubitemid 34694019)
14. Thompson, E. A., Jr.; Siiteri, P. K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione J. Biol. Chem. 1974, 249, 5364-5372
15. Simpson, E. R.; Mahendroo, M. S.; Means, G. D.; Kilgore, M. W.; Hinshelwood, M. M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher, C. R.; Michael, M. D.; Mendelson, C. R.; Bulun, S. E. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis Endocr. Rev. 1994, 15, 342-355 (Pubitemid 24180792)
16. Akhtar, M.; Calder, M. R.; Corina, D. L.; Wright, J. N. Mechanistic studies on C-19 demethylation in oestrogen biosynthesis Biochem. J. 1982, 201, 569-580 (Pubitemid 12130317)
17. Akhtar, M.; Njar, V. C.; Wright, J. N. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes J. Steroid Biochem. Mol. Biol. 1993, 44, 375-387 (Pubitemid 23126608)
18. Eisen, A.; Trudeau, M.; Shelley, W.; Messersmith, H.; Pritchard, K. I. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review Cancer Treat. Rev. 2008, 34, 157-174
19. Mokbel, K. The evolving role of aromatase inhibitors in breast cancer Int. J. Clin. Oncol. 2002, 7, 279-283 (Pubitemid 35332286)
20. Wong, Z. W.; Ellis, M. J. First-line endocrine treatment of breast cancer: Aromatase inhibitor or antioestrogen- Br. J. Cancer 2004, 90, 20-25 (Pubitemid 38174932)
21. Milla-Santos, A.; Milla, L.; Portella, J.; Rallo, L.; Pons, M.; Rodes, E.; Casanovas, J.; Puig-Gali, M. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study Am. J. Clin. Oncol. 2003, 26, 317-322 (Pubitemid 36712651)
22. Nabholtz, J. M.; Mouret-Reynier, M. A.; Durando, X.; Van Praagh, I.; Al-Sukhun, S.; Ferriere, J. P.; Chollet, P. Comparative Review of Anastrozole, Letrozole and Exemestane in the management of early breast cancer Expert Opin. Pharmacother. 2009, 10, 1435-1447
23. Le Borgne, M.; Marchand, P.; Duflos, M.; Delevoye-Seiller, B.; Piessard-Robert, S.; Le Baut, G.; Hartmann, R. W.; Palzer, M. Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1H-indoles and 3-(1-azolyl-1- phenylmethyl)-1H-indoles as inhibitors of P450 arom Arch. Pharm. (Weinheim) 1997, 330, 141-145 (Pubitemid 27298759)
24. Leze, M. P.; Palusczak, A.; Hartmann, R. W.; Le Borgne, M. Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4713-4715
25. Arora, A.; Potter, J. F. Aromatase inhibitors: Current indications and future prospects for treatment of postmenopausal breast cancer J. Am. Geriatr. Soc. 2004, 52, 611-616 (Pubitemid 38480642)
26. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme J. Med. Chem. 2006, 49, 4777-4780 (Pubitemid 44162705)
27. Goss, P. E. Risks versus benefits in the clinical application of aromatase inhibitors Endocr. Relat. Cancer 1999, 6, 325-332 (Pubitemid 29260069)
28. Gobbi, S.; Cavalli, A.; Negri, M.; Schewe, K. E.; Belluti, F.; Piazzi, L.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Imidazolylmethylbenzophenones as highly potent aromatase inhibitors J. Med. Chem. 2007, 50, 3420-3422 (Pubitemid 47195449)
29. Saberi, M. R.; Vinh, T. K.; Yee, S. W.; Griffiths, B. J.; Evans, P. J.; Simons, C. Potent CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: Synthesis and biological evaluation J. Med. Chem. 2006, 49, 1016-1022 (Pubitemid 43221649)
30. Gobbi, S.; Zimmer, C.; Belluti, F.; Rampa, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Novel highly potent and selective nonsteroidal aromatase inhibitors: Synthesis, biological evaluation and structure-activity relationships investigation J. Med. Chem. 2010, 53, 5347-5351
31. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R. W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors J. Med. Chem. 2004, 47, 6792-6803 (Pubitemid 40053767)
32. Berman, H.; Henrick, K.; Nakamura, H. Announcing the worldwide Protein Data Bank Nat. Struct. Biol. 2003, 10, 980 (Pubitemid 37500485)
33. Favia, A. D.; Cavalli, A.; Masetti, M.; Carotti, A.; Recanatini, M. Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes Proteins 2006, 62, 1074-1087 (Pubitemid 43364170)
34. Neves, M. A.; Dinis, T. C.; Colombo, G.; Sa e Melo, M. L. Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors J. Med. Chem. 2009, 52, 143-150
35. Castellano, S.; Stefancich, G.; Ragno, R.; Schewe, K.; Santoriello, M.; Caroli, A.; Hartmann, R. W.; Sbardella, G. CYP19 (aromatase): Exploring the scaffold flexibility for novel selective inhibitors Bioorg. Med. Chem. 2008, 16, 8349-8358
36. Baston, E.; Leroux, F. R. Inhibitors of steroidal cytochrome P450 enzymes as targets for drug development Recent Pat. Anticancer Drug Discovery 2007, 2, 31-58 (Pubitemid 46729085)
37. Zhuang, Y.; Wachall, B. G.; Hartmann, R. W. Novel imidazolyl and triazolyl substituted biphenyl compounds: Synthesis and evaluation as nonsteroidal inhibitors of human 17alpha-hydroxylase/C17, 20-lyase (P450 17) Bioorg. Med. Chem. 2000, 8, 1245-1252 (Pubitemid 30398447)
38. Leroux, F. H. T.; Charrîre, C.; Scopelliti, R.; Hartmann, R. W. N-(4-Biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substitution- Helv. Chim. Acta 2003, 86, 2671-2686 (Pubitemid 37011982)
39. Ghosh, D.; Griswold, J.; Erman, M.; Pangborn, W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase Nature 2009, 457, 219-223
40. Ghosh, D.; Griswold, J.; Erman, M.; Pangborn, W. X-ray structure of human aromatase reveals an androgen-specific active site J. Steroid Biochem. Mol. Biol. 2010, 118, 197-202
41. Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: Development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor J. Med. Chem. 2009, 52, 6685-6706
42. Evans, D. A.; Katz, J. L.; West, T. R. Synthesis of diaryl ethers through the copper-promoted arylation of phenols with arylboronic acids. An expedient synthesis of thyroxine Tetrahedron Lett. 1998, 39, 2937-2940 (Pubitemid 28184064)
43. Atkins, R. L.; Bliss, D. E. Substituted coumarins and azocoumarins. Synthesis and fluorescent properties J. Org. Chem. 1978, 43, 1975-1981
44. Chan, D. M. T.; Monaco, K. L.; Wang, R. P.; Winters, M. P. New N- and O-arylations with phenylboronic acids and cupric acetate Tetrahedron Lett. 1998, 39, 2933-2936 (Pubitemid 28184063)
45. Kotwani, N. G.; Sethna, S. M.; Advani, G. D. Pechmann condensation of phenols with ethyl-phenylacetoacetate J. Univ. Bombay, Sci.: Phys. Sci., Math., Biol. Sci. Med. 1942, 10, 143-147
46. Selwood, D. L.; Brummell, D. G.; Budworth, J.; Burtin, G. E.; Campbell, R. O.; Chana, S. S.; Charles, I. G.; Fernandez, P. A.; Glen, R. C.; Goggin, M. C.; Hobbs, A. J.; Kling, M. R.; Liu, Q.; Madge, D. J.; Meillerais, S.; Powell, K. L.; Reynolds, K.; Spacey, G. D.; Stables, J. N.; Tatlock, M. A.; Wheeler, K. A.; Wishart, G.; Woo, C. K. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase J. Med. Chem. 2001, 44, 78-93 (Pubitemid 32049785)
47. Britto, N.; Gore, V. G.; Mali, R. S.; Ranade, A. C. A Convenient synthesis of 3-benzyl, 3-benzyl-4-substituted coumarins and their benzo derivatives Synth. Commun. 1989, 19, 1899-1910
48. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones J. Med. Chem. 1986, 29, 1362-1369 (Pubitemid 16034622)
49. Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32 (Pubitemid 38239927)
50. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase/C(17,20)- lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63 (Pubitemid 32155424)
51. Hille, U. E.; Zimmer, C.; Vock, C. A.; Hartmann, R. W. First selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases ACS Med. Chem. Lett. 2011, 2, 2-6
52. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach J. Med. Chem. 2008, 51, 6138-6149
53. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: Lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin- 2-one derivatives J. Med. Chem. 2008, 51, 8077-8087
54. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Marchais-Oberwinkler, S.; Klein, C. D. P.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: Potent inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1796-1805 (Pubitemid 40396312)
55. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Barassin, C.; Marchais-Oberwinkler, S.; Hartmann, R. W. Heteroaryl substituted naphthalenes and structurally modified derivatives: Selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis J. Med. Chem. 2005, 48, 6632-6642 (Pubitemid 41504720)
56. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR Hydrophobic, Electronic, and Steric Constants; American Chemical Society: Washington, DC, 1995; Vol. 2.
57. D'Acquarica, I.; Gasparrini, F.; Misiti, D.; Villani, C.; Carotti, A.; Cellamare, S.; Muck, S. Direct chromatographic resolution of carnitine and O-acylcarnitine enantiomers on a teicoplanin-bonded chiral stationary phase J. Chromatogr. A 1999, 857, 145-155 (Pubitemid 29436036)
58. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking J. Med. Chem. 2009, 52, 397-406
59. Sun, B.; Hoshino, J.; Jermihov, K.; Marler, L.; Pezzuto, J. M.; Mesecar, A. D.; Cushman, M. Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer Bioorg. Med. Chem. 2010, 18, 5352-5366
60. Karkola, S.; Wahala, K. The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: A molecular modelling study Mol. Cell. Endocrinol. 2009, 301, 235-244
61. Michaud, L. B.; Buzdar, A. U. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer Drug Saf. 1999, 21, 297-309 (Pubitemid 29465697)
62. Kennedy, R. O.; Thornes, R. D., Eds. Coumarins: Biology, Applications and Mode of Actions; John Wiley and Sons: Chichester, 1997.
63. Hirsh, J.; Dalen, J.; Anderson, D. R.; Poller, L.; Bussey, H.; Ansell, J.; Deykin, D. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 2001, 119, 8S-21S (Pubitemid 32154192)
64. Pelkonen, O.; Raunio, H.; Rautio, A.; Pasanen, M.; Matti, A. L. The metabolism of coumarin. In Coumarins: Biology, Applications and Mode of Actions; O'Kennedy, R.; Thornes, R. D., Eds.; John Wiley and Sons: Chichester, 1997.
65. Seliger, B. The effects of coumarin and its metabolites on cell growth and development. In Coumarins: Biology, Applications and Mode of Actions; O'Kennedy, R.; Thornes, R. D., Eds.; John Wiley and Sons: Chichester, 1997.
66. Pelkonen, O.; Rautio, A.; Raunio, H.; Pasanen, M. CYP2A6: A human coumarin 7-hydroxylase Toxocology 2000, 144, 139-147 (Pubitemid 30201630)
67. Touchstone, J. Advances in Thin-Layer Chromatography: John Wiley & Sons: New York, 1982.
68. Wachall, B. G.; Hector, M.; Zhuang, Y.; Hartmann, R. W. Imidazole substituted biphenyls: A new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer Bioorg. Med. Chem. 1999, 7, 1913-1924 (Pubitemid 29457689)
69. Cole, J. C.; Murray, C. W.; Nissink, J. W.; Taylor, R. D.; Taylor, R. Comparing protein-ligand docking programs is difficult Proteins 2005, 60, 325-332 (Pubitemid 41061629)
70. MacroModel, version 9.8; Schrödinger, LLC, New York, NY, 2010.
71. Schrödinger Suite 2009 Induced Fit Docking protocol; Glide, version 5.5, Schrödinger, LLC: New York, NY, 2009; Prime, version 2.1; Schrödinger, LLC: New York, NY, 2009.